NCT07531745: ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 32 planned
- Started
- 21 May 2026
- Primary completion
- Dec 2030
- Arms
- Part 1: Single Ascending Dose (SAD): Dose Level 1, Part 1: SAD: Dose Level 2, Part 1: SAD: Dose Level 3, Part 1: SAD: Dose Level 4, Part 2: Multiple Ascending Dose (MAD): Dose Level 1-4
- Results
- None posted
- 15 Apr 2026: Trial registered
- 21 May 2026: Trial started